As of 1 January 2027, Novo Nordisk will lower the list price, or wholesale acquisition cost, to $675 for Wegovy (semaglutide) ...

Incyte Biosciences UK has received NICE approval for eligible NHS patients with non-segmental vitiligo to be reimbursed for Opzelura (ruxolitinib) cream 15mg/g. This comes after more than two years of ...

Proud to be ranked 3rd among the Top 10 UK-focused agencies, along with other categories, Grace Communications finds inspiration in being included in PMLive’s Top 40 Creative Healthcare Agencies 2025.

Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve ...

“The UK Singapore Chamber Trade Accelerator is a great initiative to help fast-track world-class UK innovation into one of ...

For the millions of people living with a rare disease, the path to a diagnosis (if ever received) is often a long and ...

The board will support the CGT Catapult in identifying and removing barriers to the widespread adoption of advanced therapies ...

COVID-19 showed how quickly a health emergency becomes a fiscal event: disrupting supply chains, reshaping capital allocation ...

The campaign repositions what is perceived as ‘normal’ in women’s health to support WOMEN | Bayer’s core message: ‘If it’s ...

The NIRSE-GAL study, conducted in Galicia, Spain, is the first prospective real-world population study to evaluate the impact ...

Competitive advantage: In a crowded therapeutic landscape, the ability to adapt quickly based on payer feedback can be a key ...

In the world of rare diseases, success is often measured by the speed of diagnosis. However, for women facing rare liver ...